Methods of treating autoimmune disease via CTLA-4Ig
AssigneesThe Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
InventorsCraig B. Thompson, Carl H. June
Life of this patent
Estimating the term…
Abstract
The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.
Claims20
A method of treating a patient having multiple sclerosis comprising administering to the patient CTLA-4Ig in an amount effective to suppress the patient's immune response.
A method of treating a patient having systemic lupus erythematosis comprising administering to the patient CTLA-4Ig in an amount effective to suppress the patient's immune response.
A method of treating a patient having rheumatoid arthritis comprising administering to the patient CTLA-4Ig in an amount effective to suppress the patient's immune response.
A method of treating a patient having scleroderma comprising administering to the patient CTLA-4Ig in an amount effective to suppress the patient's immune response.
Dependencies are inferred from the claim text.